REG - Renalytix PLC - Management Change

RenalytixAnnouncement

18/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240418:nRSR0516La&default-theme=true

RNS Number : 0516L  Renalytix PLC  18 April 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Renalytix Announces Management Change - Howard Doran Promoted to President

 

LONDON and SALT LAKE CITY, 18 April 2024 - Renalytix plc
(https://renalytix.com/) (NASDAQ: RNLX) (LSE: RENX) announces that Howard
Doran, who has served as the Company's Chief Business Officer since September
2023, has been appointed as President, effective April 30, 2024. Thomas
McLain, who has served as the Company's President since July 2019, is
stepping down effective that date.

 

James McCullough, Renalytix CEO, said:

"We thank Tom for his many accomplishments in helping Renalytix achieve the
tri-fecta of broad insurance coverage, FDA regulatory approval and real-world
outcomes evidence that now positions KidneyIntelX for commercial adoption.

 

"Howard assumes the position of President to lead the global sales effort
having now built our sales team from individuals with leading industry sales
track records."

 

For further information, please contact:

 

 Renalytix plc                                                                 www.renalytix.com (http://www.renalytix.com)

 James McCullough, CEO                                                         Via Walbrook PR

 Stifel (Nominated Adviser to the Company)                                     Tel: 02077107600

 Nicholas Moore / Alex Price / Nick Harland / Samira Essebiya / Harry Billen

 Investec Bank plc                                                             Tel: 020 7597 4000

 Gary Clarence / Shalin Bhamra

 Walbrook PR Limited                                                           Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                                                             (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings / Charlotte Edgar

                                                                               Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

 CapComm Partners                                                              Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 Peter DeNardo

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIRMTTMTTBTRI